Harrow Health Inc (HROW)
Harrow Acquires U.S. Commercial Rights toBYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
Harrow Acquires U.S. Commercial Rights toBYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
There are no comments here yet...